At Pathalys Pharma, Inc. we are committed to improving the lives of patients through the development of enhanced therapeutics that improve the management of chronic kidney disease (CKD).
Pathalys is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in the management of late stage chronic kidney disease (CKD).
THE PROBLEM
While advancements have been made, many critical unmet needs remain. For Pathalys, these unmet needs are our call-to-action.
One such unmet need and an initial area of focus for Pathalys is the improved treatment for secondary hyperparathyroidism (SHPT). SHPT is a condition in which a disease outside of the parathyroid glands causes all the parathyroid glands to become enlarged and hyperactive, overproducing parathyroid hormone (PTH).
The most common causes of SHPT are kidney failure and vitamin D deficiency. In kidney failure, the kidney is no longer able to make enough vitamin D or remove all the phosphorus that is made by the body, which leads to low calcium levels.
These low calcium levels stimulate the parathyroid glands to make more PTH. Over time, this constant stimulation causes the parathyroid glands to grow and become hyperactive and patients can progress to develop SHPT.1
THE SOLUTION
Beyond upacicalcet, Pathalys continues to identify high priority needs and potential solutions for patients with end-stage kidney disease.
Research Triangle Park, N.C., April 8, 2022 – Pathalys Pharma, Inc., a private, late-stage biopharma company committed to the development and commercialization of a range
– Plans for Phase 3 Program Presented at National Kidney Foundation’s Annual Spring Clinical Meeting – Research Triangle Park, N.C., April 7, 2022 – Pathalys
– Executive Leadership Team Brings Diverse Skills and Broad Expertise to New Venture – RESEARCH TRIANGLE PARK, N.C., March 30, 2022 – Pathalys Pharma, Inc.,